New insulin collaboration
Warsaw – Polish drugmaker Bioton S.A. and Iceland-based generics firm Actavis Group ptc announced in January that they are entering into a marketing and distribution collaboration agreement for Bioton’s insulins and insulin analogs. Under the terms of an initial agreement, Bioton will be responsible for the development, manufacture and registration of the products in different markets. Actavis is set to take responsibility for marketing and distribution. The companies plan to share the costs of product development and sales profits equally. In September, Actavis opened talks with Bioton on the acquisition of 51% of Bioton’s shares in Swiss Biopartners Holdings. Actavis said that it will decide on that option after having finished the insulin deal.